Prescription Drug Matzim LA Extended-Release Tablets Recalled for Failed Dissolution
Teva Pharmaceuticals is recalling Matzim LA (Diltiazem Hydrochloride) 180 mg tablets because they failed to meet dissolution specifications. The recall affects approximately 8,022 bottles distributed nationwide in the United States and Puerto Rico.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II designation indicates potential for adverse health consequences; this is a cardiac medication with failed dissolution specifications, representing a risk-of-harm product where no illnesses or injuries have been reported, consistent with High (Score 3) per the severity rubric.
Plain-English summary
Teva Pharmaceuticals USA Inc is recalling Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, due to failed dissolution specifications. The affected tablets did not meet dissolution specification limits.
The recall involves approximately 8,022 bottles with lot number 1411593A and expiration date 09/22. The product was distributed nationwide in the United States and Puerto Rico.
The extended-release formulation with NDC number 52544-691-30 is manufactured by Actavis Laboratories FL, Inc. and distributed by Actavis Pharma, Inc. These tablets are prescription-only medication.
The recalled product
- Product
- MATZIM LA (DILTIAZEM HYDROCHLORIDE)
- Brand
- MATZIM LA
- Manufacturer
- Teva Pharmaceuticals USA Inc
- Category
- Drug — Extended-Release Tablet
- Hazard
- Affected units
- 8,022
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 1411593A
- Exp 09/22
Distribution
Part of a larger recall action
This product is one of 2 recalled by Teva Pharmaceuticals USA Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · MATZIM LA
- LowTeva Recalls Matzim LA Tablets Due to GMP Deviation
FDA (Drugs) · 2019-10-16
Same manufacturer · Teva Pharmaceuticals USA Inc
See all →- SevereOctreotide Acetate Injectable Suspension Recalled Due to Sterility Assurance
FDA (Drugs) · 2026-05-13
- ModerateClaravis isotretinoin 10 mg capsules recalled for out-of-specification impurity
FDA (Drugs) · 2026-04-29
- ModerateTeva clonidine 0.2 mg patches recalled over unapproved raw material use
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 30 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
- HighTeva isotretinoin 40 mg capsules recalled as superpotent and subpotent
FDA (Drugs) · 2026-04-15
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17